Document is current
Any future updates will be listed below
-
Authors
Sun, Xiaoqi https://orcid.org/0000-0003-0752-1928
Zhou, Xingwu https://orcid.org/0000-0001-5977-2185
Shi, Xiaoyue
Abed, Omar A. https://orcid.org/0000-0002-3854-2249
An, Xinran
Lei, Yu Leo
Moon, James J. https://orcid.org/0000-0003-2238-2372
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R01DE030691, R01DE031951, R01DE026728)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125087)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA271799, U01CA210152, P30CA046592, R44CA281497)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS122536)
- License Information
-
More Information
Article History
Received: 21 October 2022
Accepted: 30 March 2024
First Online: 24 June 2024
Competing interests
: X. Sun is an employee and shareholder of Editas Medicine. Y.L.L. is a co-founder of Saros Therapeutics and serves on its scientific advisory board. J.J.M. declares financial interests in EVOQ Therapeutics and Saros Therapeutics as a board member, paid consultant and equity holder, and as a recipient of research funding. The University of Michigan also has financial interest in EVOQ Therapeutics.
